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Background: The management of osteoarthritis (OA) remains a challenge. There is a need not only for safe and
efficient treatments but also for accurate and reliable biomarkers that would help diagnosis and monitoring both
disease activity and treatment efficacy. Curcumin is basically a spice that is known for its anti-inflammatory properties. In
vitro studies suggest that curcumin could be beneficial for cartilage in OA. The aim of this exploratory, non-controlled
clinical trial was to evaluate the effects of bio-optimized curcumin in knee OA patients on the serum levels of specific
biomarkers of OA and on the evaluation of pain.
Methods: Twenty two patients with knee OA were asked to take 2x3 caps/day of bio-optimized curcumin (Flexofytol®)
for 3 months. They were monitored after 7, 14, 28 and 84 days of treatment. Pain over the last 24 hours and global
assessment of disease activity by the patient were evaluated using a visual analog scale (100 mm). The serum levels of
Coll-2-1, Coll-2-1NO2, Fib3-1, Fib3-2, CRP, CTX-II and MPO were determined before and after 14 and 84 days of treatment.
Results: The treatment with curcumin was globally well tolerated. It significantly reduced the serum level of
Coll2-1 (p < 0.002) and tended to decrease CRP. No other significant difference was observed with the other biomarkers.
In addition, curcumin significantly reduced the global assessment of disease activity by the patient.
Conclusion: This study highlighted the potential effect of curcumin in knee OA patient. This effect was reflected by
the variation of a cartilage specific biomarker, Coll2-1 that was rapidly affected by the treatment. These results are
encouraging for the qualification of Coll2-1 as a biomarker for the evaluation of curcumin in OA treatment.
Trial registration: NCT01909037 at clinicaltrials.gov
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Osteoarthritis (OA) is a complex arthritic condition, evolv-
ing over decades and leading to the loss of joint function.
It is characterized by the degradation of articular cartilage,
the modification of the subchondral bone and the inflam-
mation of the synovial membrane [1]. So far, none of the* Correspondence: yhenrotin@ulg.ac.be
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reproduction in any medium, provided the oravailable treatment allows the control or even better, the
arrest of the disease progression. The main recommenda-
tions for OA management concentrate on the control of
symptoms, i.e. pain and function [2-6]. This goal is sup-
posed to be achieved mostly by the use of acetaminophen
or non-steroidal anti-inflammatory drugs (NSAIDs). How-
ever, considering the potential side effects and the long
duration of treatment, one may prefer the use of less toxic
compounds. There is indeed a growing interest for food or
food-derived products, the so-called nutraceuticals [7-9]
that provide health and medical benefits with a good safety
profile.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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nutraceutical [10,11]. It is used for centuries by the
Ayurvedic and traditional Chinese medicine. Indeed, it
has demonstrated astonished properties, mainly anti-
inflammatory, against various conditions [12-18], including
arthritis [10,19-21]. Even if its bioavailability represented a
challenge for a long time, several new formulations tend to
abrogate this matter [19].
In addition to efficient therapies, OA management
requires the identification of potent biomarkers for the
monitoring of treatment efficacy [22]. Many efforts have
been carried out in that direction for the past decade.
Collagen degradation products appeared as suitable and
reliable biomarkers for OA [23].
The aim of the present study was to evaluate the ef-
fects of bio-optimized curcumin during a 90-day period
in knee OA patients during an exploratory non-controlled
clinical trial. One caps of bio-optimized curcumin con-
tains 42 mg curcumin mixed with polysorbate in a well-
defined ratio. The primary endpoint for this study was the
measurement of the serum levels of several biomarkers of
cartilage metabolism and inflammation and the secondary
endpoints were the evaluation of pain and the global
patient assessment of disease activity.
Methods
Patients and treatment
This exploratory, non-controlled clinical trial was con-
ducted at the rheumatology center of the Citadelle Hos-
pital of Liège (Belgium) in knee OA patients suffering
night pain and effusion registered as NCT01909037
(http://clinicaltrials.gov/show/NCT01909037). It was ap-
proved by the ethic committee of the Citadelle Hospital of
Liège (Belgium) (#1209). Patients were selected for their
knee OA according to the ACR criteria [24] between
March and December 2012. Inclusion and exclusion cri-
teria for patient enrollment are presented in Table 1. The
Kellgren and Lawrence radiographic score of disease se-
verity (K&L) was performed at the time of selection (V1).
Patients signed an informed consent before the beginning
of the investigation.
Patients enrolled in the study were asked to take bio-
optimized curcumin (Flexofytol ®), 3 caps in the morning
(on an empty stomach, right before breakfast) and 3 caps
in the evening for 3 months. Each caps of bio-optimized
curcumin contains 42 mg curcumin mixed with polysor-
bate (Tween 80®) in a well-defined ratio. The treatment
was delivered by the rheumatologist at the time of inclu-
sion. Patients agreed to proscribe analgesics (except acet-
aminophen, max 4 g/day) or NSAIDs during the study.
Acetaminophen was avoided 48 h prior to each visit.
The study consisted in a 3-month follow-up with 4
visits (after 7 (V2), 14 (V3), 28 (V4) and 84 (V5) days of
treatment). Pain over the last 24 h evaluation and globalpatient assessment on disease activity were recorded on
a 100 mm visual analog scale (VAS) at each visit. At the
same time, adverse events and concomitant treatments were
also recorded. Blood samples were collected at the time of
V1, V3 and V5. All assessments and data collection were
performed by the rheumatologist. No incentive to increase
compliance or adherence was proposed to the patients.
Serum biomarkers
Biological assays using specific kits were performed by
Artialis S.A. (Liège, Belgium) according to the manufac-
turer’s recommendations. Coll-2-1 (nmol/L), Coll-2-1NO2
(nmol/L), Fib3-1 (pmol/L), Fib3-2 (pmol/L), C-reactive
protein (CRP) (mg/L), CTX-II (ng/L) and myeloperoxi-
dase (MPO) (μg/L) were measured in the serum of OA
patients.
The concentration of Coll2-1 and Coll2-1NO2 were
measured by two new competitive and specific immuno-
assays (ELISA) [25]. The Coll2-1 immunoassay only mea-
sured the amino acid sequence 108HRGYPGLDG116 in
its linear form while the Coll2-1NO2 immunoassay quan-
tified with a high specificity and affinity the nitrated amino
acids sequence. The limits of detection were 17 nM for
Coll2-1 immunoassay and 25 pM for Coll2-1NO2 im-
munoassay. The intra- and inter-assay CVs were lower
than 10% and the dilution curves were parallel to the
standard curve for both assays. The analytical recoveries
were in mean 104.7% and 121.9% for Coll2-1 and Coll2-
1NO2 assays, respectively.
Fib3-1 (TCQDINECETTNECR) and Fib3-2 (CVCPVS
NAMCR) are specific peptides of fibulin-3 that are po-
tential biomarkers of osteoarthritis [26]. The immunoas-
says for measuring Fib3-1 or Fib3-2 have been developed
using polyclonal antibodies which did not recognize
complete fibulin-3 and did not cross-react between
Fib3-1 and Fib3-2. The lower detection limit of the
Fib3-1 assay was 5.2 pM. The within-run (intra-assay)
precisions and the between-run (inter-assay) precision
were below 11%. Linearity was shown by diluting sam-
ples serially and comparing the observed values with
those expected. Typical recovery rate of 85.8-104% was
noted in a range of dilution between 2 and 8 fold. Spiking
recovery, determined by the addition of known quantities
of Fib3-1 peptide (from 25 to 250 pM) into sample ranged
from 92.3% to 103.2%. The lower detection limit of the
Fib3-2 assay was 8 pM. The CVs of intra-assays and inter-
assays were below 11%. The dilution curves were parallel
to the standard curve with a typical recovery rate of 80.49-
105.13% in a range of dilution between two and eight- fold.
The recovery of spiking was between 101.3% and 112.4%.
Serum samples were twice-diluted in standard buffer.
Myeloperoxidase (MPO) was determined by a com-
mercially available ELISA kit (ELIZEN MPO, Zentech
SA, Liège, Belgium).
Table 1 Inclusion and exclusion criteria
Patients met all the following criteria
Inclusion criteria • Men or women, age 45–75;
• Medial femoro-tibial gonarthrosis (in case of bilateral OA, the most painful knee was evaluated);
• Responding to ACR criteria (clinical evaluation and radiological);
• Symptoms lasting for more than 6 months;
• Global knee pain evaluation over the last 24 hours > 40 mm (without NSAID or other analgesic
for more than 48 hours);
• K&L II to III (Kellgren and Lawrence evaluated within the last 12 months);
• Agreed to banish NSAIDs and analgesics for the duration of the study;
• Signed informed consent;
• Capable of following the study guidelines;
• With health insurance.
Exclusion criteria Patients with AT LEAST ONE of the following criteria were not enrolled in the study
• OA disease:
o Secondary OA due to metabolic arthropathy: chondrocalcinosis previously
o Known or defined by a calcium border on at least one tibiofemoral joint space, gout,…
o Predominant symptomatic femoropatellar OA;
o Chondromatosis or villo-nodular synovitis of the knee;
o Paget’s disease;
o Ipsilateral coxarthrosis to the known and symptomatic gonarthrosis;
o Recent knee trauma (<1 month) responsible for pain;
o Pathologies that could interfere with evaluation (inflammatory and metabolic arthropathy,
rheumatoid arthritis, lower limb radiculalgia, arteritis,…).
o Joint prosthesis (any site)
o Flare affecting another joint
• Related to anterior and associated treatments:
o Corticosteroid infiltration received to any joint in the month prior enrollment;
o Infiltration of hyaluronic acid in the evaluated knee within 6 months before enrollment;
o Taking NSAIDs or analgesics in the last 48 hours prior to inclusion;
o No changes in their slow-acting anti-OA drugs and anti-OA dietary supplements over the last
6 months (e.g. chondroitin sulfate, diacerein, avocado soybean unsaponifiables, oxaceprol, copper,
glucosamine , anti-OA herbal therapy and homeopathy, …);
o Taking coumarin anticoagulants and heparins;
o General corticosteroid;
o Contraindication to paracetamol.
• About the product:
o Contraindication to the product (Flexofytol)
• Related to associated pathologies:
o Serious associated diseases (severe liver failure, renal failure, uncontrolled cardiovascular diseases, …).
• Regarding the patients:
o Pregnant or lactating women;
o Premenopausal women not using a contraceptive method;
o Patient unable to write;
o Patient who participated in a clinical research in the previous 3 months;
o Legally responsible adults.
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Table 2 Demographic data and OA history
Patients
N 22 (M: 7-F: 15)
Age 64.3 ± 8.4 years
























V1 22 22 - - -
V2 22 9.1% 50.0%
(7 days)
V3 22 22 14.3% 45.4% 1
(14 days)
V4 21 14.3% 35.0% 1
(28 days)
V5(84 days) 20 20 25% 55.6%
V1: first visit, at the time of selection; V2: visit after 7 days of treatment ; V3:
visit after 14 days of treatment; V4: visit after 28 days of treatment; V5: visit
after 84 days of treatment.
Knee OA patients with night pain and effusion were asked to take 2x3 caps of
an enriched curcumin extract twice a day for 3 months from V1. They were
visited after 7, 14, 28 and 84 days of treatment.
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determined by a highly sensitive immunonephelometric
method (DADE Behring, Milan, Italy) on a BN II Analyzer.
The lower limit of detection was 0.175 mg/l (analytical
sensitivity 0.04 mg/l).
Urinary C-Terminal telopeptides of type II Collagen
(U-CTX-II) was assayed with a competitive ELISA based on
a monoclonal antibody raised against the EKGPDP linear
six-amino acid epitope of the type II collagen C telopeptide
(CartiLaps®, Nordic Biosciences, Herlev, Denmark) [27].
Statistical analysis
The results are expressed as mean, standard deviation
(SD) and range for quantitative variables and as fre-
quency tables (numbers and percent) for categorized
variables. A log-transform was applied to data in case of
non-normality. The evolution of pain assessment, judg-
ment against the disease and biomarkers with time was an-
alyzed using a Generalized Linear Mixed Model (GLMM).
This model takes into account that time-related measure-
ments within patients. Calculations were made on the
maximum data available. The results were considered sig-
nificant at 5% significance level (p <0.05). The calculations
were performed using the SAS (version 9.3 for Windows).
Results
Patients and safety
Twenty two patients (7 males (31.8%) and 15 females
(68.2%)) were included in the study. They were 64.3 ±
8.39 years old (ranging 49 to 77). Patients’ disease his-
tory is summarized in Table 2. They all have pain for
years. K&L radiographic severity score was mostly II
(50.0%) and III (31.8%) revealing moderate to severe
OA. Among the recruited patients, 59.1% of patients suf-
fered night pain and 31.8% have knee effusion, reflecting
the inflammatory status of the disease.
Among the 22 patients recruited in the study, 20 com-
pleted the study. One patient discontinued the study
after V3 (after14 days of treatment) due to diarrhea and
vomiting and another one after V4 (after 28 days of
treatment) due to nausea and vomiting. The safety, ad-
verse events and drop out are presented Table 3. A good
observance of the treatment was recorded throughout
the study. The observed adverse events were minor and
related to gastro-intestinal problems.
Primary endpoint: serum levels of biomarkers
Several biomarkers were measured in the serum of pa-
tients during the study (Table 4). The intake of curcumin
induced a significant and systematic reduction of Coll2-
1 (P = 0.002 between V1 and V5). A decrease of serum
Coll2-1 level was recorded in all patients. Otherwise no
significant effect was observed on the other tested bio-
markers. However, there was a 77% decrease of CRP inthe serum of patients taking curcumin for 3 months, but
this effect was not significant most probably due to wide
variability of the CRP levels at baseline.
Secondary endpoints: pain over the last 24 hours and
global assessment of disease activity
The mean values obtained for the secondary endpoints
are reported Table 5. The pain over the last 24 hours
evaluated on a VAS (100 mm) tended to decrease (by
22% in mean) under treatment with curcumin. However,
this reduction was not significant most probably due to















V1 302.21 ± 53.78 0.71 ± 0.18 707.05 ± 178.79 580.58 ± 103.09 10.42 ± 30.27 11.81 ± 7.98 27.20 ± 29.05
V3 315.37 ± 62.35 0.77 ± 0.20 736.05 ± 157.16 600.90 ± 86.04 3.82 ± 3.29 12.12 ± 5.98 20.46 ± 13.15
V5 257.84 ± 52.78 0.80 ± 0.24 765.20 ± 261.90 636.74 ± 119.73 3.10 ± 2.40 13.17 ± 4.96 21.96 ± 14.65
P = 0.002*
*p value versus V1. Data are mean ± sd and were analyzed with Student t-test. V1: first visit, at the time of selection; V3: visit after 14 days of treatment; V5: visit
after 84 days of treatment.
Henrotin et al. BMC Complementary and Alternative Medicine 2014, 14:159 Page 5 of 7
http://www.biomedcentral.com/1472-6882/14/159wide variability of response. Nevertheless, a significant
lessening of the global assessment of disease activity by the
patients was observed between V1 and V5 (P = 0.0047).
Discussion
This study showed that bio-optimized curcumin was
associated with a decrease of the level of a specific bio-
marker of OA and improving of the global assessment of
the disease by the patient. In addition, the treatment was
globally well tolerated with a low drop-out rate, minor
adverse effects (mainly nausea) and a good observance.
This bio-optimized curcumin is an enriched formulation
of curcumin (42 mg/caps) with an enhanced bioavailabil-
ity that might be responsible at least in part for this
effect. Indeed, at the dose use in this study, the bio-
optimized curcumin has a Cmax statistically extrapo-
lated around 2 μM, which is the concentration that
produced significant effect in vitro [19]. The used dose
has been determined after a phase I pharmacokinetic
study on Flexofytol®. In this trial 2 groups of 12 healthy in-
dividuals received orally 1 (42 mg curcumin) or 2 capsules
(84 mg of curcumin) of Arantal® respectively. With 2
capsules administered orally, the mean of Cmax on 12
individuals was 0.9 μM, with a statistical extrapolation
at 1.6 μM with 4 capsules (84 mg and 168 mg of cur-
cumin respectively) [19]. In vitro, curcumin significantly
inhibits pro-inflammatory cytokines and prostanoids, and
matrix-metalloproteases by chondrocytes [10,28]. More-
over, it is also able to promote chondrogenesis [29] and toTable 5 Secondary endpoints - pain over the last 24 hours
and global patient assessment on disease activity evaluated
at each visit on a VAS (100 mm)
N Pain (VAS) P value Disease activity P value
V1 22 49.41 ± 24.94 ns 60.00 ± 22.67 ns
V2 22 50.95 ± 23.85 ns 58.32 ± 20.37 ns
V3 21 44.52 ± 27.41 ns 48.71 ± 27.37 ns
V4 20 42.20 ± 26.33 ns 42.70 ± 25.82 ns
V5 20 39.20 ± 28.96 ns 38.85 ± 27.66 0.0047*
*p value versus V1. Data are mean ± sd and were analyzed with Student t-test.
V1: first visit, at the time of selection; V2: visit after 7 days of treatment; V3: visit
after 14 days of treatment; V4: visit after 28 days of treatment; V5: visit after
84 days of treatment.block tumor necrosis factor (TNF) action and production
both in vitro and in vivo [30].
Coll2-1 and its nitrated form, Coll2-1 NO2, are specific
biomarkers of OA. They have been tested in animals
[31-34] and humans [35-39]. Coll2-1 is the only one bio-
marker that was affected by the treatment with curcu-
min in this study. Coll2-1 is a peptide of type II collagen
molecule detected after collagen triple helix unwounding
and digestion by gelatinases. This finding suggests that
bio-optimized curcumin could reduce cartilage matrix
degradation. This hypothesis is supported by the in vitro
observation showing that curcumin inhibits MMP-9
production by chondrocytes [40].
In addition, Coll2-1 decrease is concomitant with an
improvement of the global assessment of disease activity
by the patients. This property of the bio-optimized cur-
cumin is of major importance when considering the
inflammatory status of the disease and its importance in
the disease process [41,42].
These significant results are accompanied by less marked
variations. Indeed, the pain over the last 24-hours esti-
mated at each visit and the serum level of CRP decrease
over the study duration. However, most probably due to
the wide variety of response, they didn’t come out signifi-
cant. Nevertheless, they both document the potential effect
of bio-optimized curcumin in knee OA patient at reducing
pain and are in favor of its anti-inflammatory effect.
Patients were asked to take curcumin for 3 months
and the follow-up didn’t go further. The short duration
of the follow-up might explain the lack of significance of
some of the results. A longer survey may have revealed
stronger potencies of curcumin.
Of course this study is exploratory and suffers of some
limitations including the small sample size and the ab-
sence of control group. However, this study has allowed
the identification of a biochemical marker which is sen-
sitive to curcumin. This marker will be helpful for phase
II and III clinical trials to monitor drug efficacy. It could
also serve as marker to follow the efficacy of bio-
optimized curcumin in the daily practice. In addition,
this pilot study shows for the first time that orally ad-
ministrated curcumin is active in OA and suggests that
this compound positively modulate the metabolism of
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opment of this compound for the management of OA
disease.
Conclusion
In conclusion, the use of curcumin under improved for-
mulation in knee OA patients appears as a good comple-
ment to classical treatments. The precise mechanism of
action should be documented in OA patient. This study
highlighted the importance of relevant and accurate bio-
markers to monitor disease activity and to evaluate the
efficacy of a treatment. These results are encouraging for
the validation of Coll2-1 as a biomarker for the evalu-
ation of a treatment for OA.
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